{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:47:49Z","timestamp":1787593669816,"version":"build-2736575974"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001117","name":"American Foundation for AIDS Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1048536"],"award-info":[{"award-number":["1048536"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH AIDS Reagent Program"},{"name":"Division of AIDS"},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Polyclonal Anti-Human Immunodeficiency Virus Immune Globulin","award":["ARP-3957"],"award-info":[{"award-number":["ARP-3957"]}]},{"name":"8E5 HIV-infected T cell line","award":["ARP-95"],"award-info":[{"award-number":["ARP-95"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Enhancement of antibody-dependent cellular cytotoxicity is a promising adjunct approach to achieve HIV control in the absence of antiretroviral therapy but requires the development of potent antibody-dependent cellular cytotoxicity\u2013eliciting antibodies that can recognize diverse HIV-infected cell types. A panel of broadly neutralizing antibodies targeting the HIV envelope was identified that specifically binds both HIV-infected CD4+ T cells and monocyte-derived macrophages. Afucosylated versions of these broadly neutralizing antibodies containing \u224830% less core fucose were generated and elicited a significant increase in antibody-dependent cellular cytotoxicity responses from natural killer cells against HIV-infected T-cell and monocyte-derived macrophage targets. Afucosylation did not alter virus neutralization or cell-binding activity of these broadly neutralizing antibodies. Afucosylation modification of broadly neutralizing antibody Fc regions is thus a promising strategy to enhance Fc-mediated activity against both T-cell and macrophage targets in vivo, which may be employed to heighten the therapeutic potential of antibody-based immunotherapy approaches for drug-free HIV control.<\/jats:p>","DOI":"10.1093\/jleuko\/qiaf033","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:48:23Z","timestamp":1741999703000},"source":"Crossref","is-referenced-by-count":6,"title":["Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell\u2013mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets"],"prefix":"10.1093","volume":"117","author":[{"given":"Olivia","family":"Wilhelm","sequence":"first","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne , 792 Elizabeth St, Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jordan","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Kek","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Immunology, School of Translational Medicine, Monash University , Level 6, 99 Commercial Rd, Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane M","family":"Brunton-O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rikard-Bell","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne , 792 Elizabeth St, Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradhipa","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne , 792 Elizabeth St, Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy W","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne , 792 Elizabeth St, Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Poumbourios","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Microbiology, Monash University , 19 Innovation Walk, Clayton, VIC 3800 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D","family":"Wines","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Immunology, School of Translational Medicine, Monash University , Level 6, 99 Commercial Rd, Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jaworowski","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Monash University , Level 2, 85 Commercial Rd, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"School of Health and Biomedical Sciences, RMIT University , Plenty Rd, Bundoora, VIC 3083 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8492-9815","authenticated-orcid":false,"given":"Anna C","family":"Hearps","sequence":"additional","affiliation":[{"name":"Life Sciences Discipline, Burnet Institute , GPO Box 284, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Monash University , Level 2, 85 Commercial Rd, Melbourne, VIC 3004 ,","place":["Australia"]},{"name":"Department of Infectious Diseases, University of Melbourne , 792 Elizabeth St, Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2025052612464699400_qiaf033-B1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3389\/fimmu.2019.01435","article-title":"The HIV reservoir in monocytes and macrophages","volume":"10","author":"Wong","year":"2019","journal-title":"Front Immunol"},{"key":"2025052612464699400_qiaf033-B2","doi-asserted-by":"publisher","first-page":"100342","DOI":"10.1016\/j.jve.2023.100342","article-title":"The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review","volume":"9","author":"Debrabander","year":"2023","journal-title":"J Virus Erad"},{"key":"2025052612464699400_qiaf033-B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2025052612464699400_qiaf033-B4","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat Med"},{"key":"2025052612464699400_qiaf033-B5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"2025052612464699400_qiaf033-B8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B9","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat Commun"},{"key":"2025052612464699400_qiaf033-B10","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.4049\/jimmunol.174.4.2185","article-title":"Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251","volume":"174","author":"Gomez-Roman","year":"2005","journal-title":"J Immunol"},{"key":"2025052612464699400_qiaf033-B11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1089\/08892220260387940","article-title":"Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS","volume":"18","author":"Banks","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025052612464699400_qiaf033-B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1023\/a:1011087132180","article-title":"Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection","volume":"21","author":"Ahmad","year":"2001","journal-title":"J Clin Immunol"},{"key":"2025052612464699400_qiaf033-B13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/08892220151126661","article-title":"Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count","volume":"17","author":"Forthal","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025052612464699400_qiaf033-B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/QAI.0b013e31822c62b9","article-title":"Activation of NK cells by ADCC antibodies and HIV disease progression","volume":"58","author":"Chung","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052612464699400_qiaf033-B15","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.xcrm.2021.100254","article-title":"Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts","volume":"2","author":"Yaffe","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025052612464699400_qiaf033-B16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"2025052612464699400_qiaf033-B17","doi-asserted-by":"publisher","first-page":"e0182521","DOI":"10.1128\/mbio.01825-21","article-title":"The HIV Env glycoprotein conformational states on cells and viruses","volume":"13","author":"Zhao","year":"2022","journal-title":"mBio"},{"key":"2025052612464699400_qiaf033-B18","doi-asserted-by":"publisher","first-page":"105085","DOI":"10.1016\/j.antiviral.2021.105085","article-title":"Differential expression of HIV envelope epitopes on the surface of HIV-infected macrophages and CD4+ T cells","volume":"191","author":"Kek","year":"2021","journal-title":"Antiviral Res."},{"key":"2025052612464699400_qiaf033-B19","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"key":"2025052612464699400_qiaf033-B20","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1080\/19420862.2016.1218586","article-title":"The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor","volume":"8","author":"Subedi","year":"2016","journal-title":"MAbs"},{"key":"2025052612464699400_qiaf033-B21","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052612464699400_qiaf033-B22","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem"},{"key":"2025052612464699400_qiaf033-B23","doi-asserted-by":"publisher","first-page":"929895","DOI":"10.3389\/fimmu.2022.929895","article-title":"Role of Fc core fucosylation in the effector function of IgG1 antibodies","volume":"13","author":"Golay","year":"2022","journal-title":"Front Immunol"},{"key":"2025052612464699400_qiaf033-B24","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1172\/JCI65708","article-title":"Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity","volume":"123","author":"Ackerman","year":"2013","journal-title":"J Clin Invest"},{"key":"2025052612464699400_qiaf033-B25","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1074\/jbc.RA117.000537","article-title":"Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion","volume":"293","author":"Narasimhulu","year":"2018","journal-title":"J Biol Chem"},{"key":"2025052612464699400_qiaf033-B26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/bit.26904","article-title":"Impact of cell culture media additives on IgG glycosylation produced in Chinese hamster ovary cells","volume":"116","author":"Ehret","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"2025052612464699400_qiaf033-B27","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1002\/cti2.1474","article-title":"Antibody glycosylation correlates with disease progression in SIV-Mycobacterium tuberculosis coinfected cynomolgus macaques","volume":"12","author":"Haycroft","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"2025052612464699400_qiaf033-B28","doi-asserted-by":"publisher","first-page":"e0022721","DOI":"10.1128\/JVI.00227-21","article-title":"Development of a novel in vitro primary human monocyte-derived macrophage model to study reactivation of HIV-1 transcription","volume":"95","author":"Wong","year":"2021","journal-title":"J Virol"},{"key":"2025052612464699400_qiaf033-B29","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.4049\/jimmunol.1402448","article-title":"An NK cell population lacking FcRgamma is expanded in chronically infected HIV patients","volume":"194","author":"Zhou","year":"2015","journal-title":"J Immunol"},{"key":"2025052612464699400_qiaf033-B30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"2025052612464699400_qiaf033-B32","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.celrep.2014.04.001","article-title":"Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike","volume":"7","author":"Scharf","year":"2014","journal-title":"Cell Rep"},{"key":"2025052612464699400_qiaf033-B33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B34","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.4049\/jimmunol.178.10.6596","article-title":"Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate","volume":"178","author":"Forthal","year":"2007","journal-title":"J Immunol"},{"key":"2025052612464699400_qiaf033-B35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41467-022-28250-7","article-title":"Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis","volume":"13","author":"Spencer","year":"2022","journal-title":"Nat Commun"},{"key":"2025052612464699400_qiaf033-B36","doi-asserted-by":"publisher","first-page":"eabe3349","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates","volume":"13","author":"Hangartner","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025052612464699400_qiaf033-B37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J Clin Invest"},{"key":"2025052612464699400_qiaf033-B38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"2025052612464699400_qiaf033-B39","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.4049\/jimmunol.1002600","article-title":"Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12","volume":"185","author":"Forthal","year":"2010","journal-title":"J Immunol"},{"key":"2025052612464699400_qiaf033-B40","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1128\/JVI.00491-12","article-title":"A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques","volume":"86","author":"Moldt","year":"2012","journal-title":"J Virol"},{"key":"2025052612464699400_qiaf033-B41","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"key":"2025052612464699400_qiaf033-B42","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"2025052612464699400_qiaf033-B43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/COH.0000000000000796","article-title":"Engineering strategies of Anti-HIV antibody therapeutics in clinical development","volume":"18","author":"Pihlstrom","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"key":"2025052612464699400_qiaf033-B44","doi-asserted-by":"publisher","first-page":"893648","DOI":"10.3389\/fimmu.2022.893648","article-title":"Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions","volume":"13","author":"Schriek","year":"2022","journal-title":"Front Immunol"},{"key":"2025052612464699400_qiaf033-B45","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s42003-024-06659-8","article-title":"Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing","volume":"7","author":"de Taeye","year":"2024","journal-title":"Commun Biol"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jleukbio\/advance-article-pdf\/doi\/10.1093\/jleuko\/qiaf033\/62416317\/qiaf033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/117\/5\/qiaf033\/62416317\/qiaf033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/117\/5\/qiaf033\/62416317\/qiaf033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T16:46:55Z","timestamp":1748278015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/doi\/10.1093\/jleuko\/qiaf033\/8078777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jleuko\/qiaf033","relation":{},"ISSN":["1938-3673"],"issn-type":[{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,15]]},"article-number":"qiaf033"}}